ImmuCell Corporation
ImmuCell develops and sells animal health products for dairy and beef cattle. The company operates two segments: Scours and Mastitis. Products include First Defense, Tri-Shield First Defense, California Mastitis Test, and Dual-Force First Defense. A new product, Re-Tain Drug Product, is being developed for subclinical mastitis treatment. ImmuCell sells products through animal health distributors. The company was incorporated in 1982 and is headquartered in Portland, Maine.
Overview
Strengths
- Skin in the game: insiders own 32% of the shares, aligning management with shareholders.
- Improving fundamentals over the last year: return on assets up 2.3 points, gross margin up 11.4 points and asset turnover up 10.6%.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 7 years.
- Unstable profitability: operating margin ranged from -33% to 6% over the last 7 years, with operating losses in 5 of them.
- Valued at a premium to its Biotechnology peers: P/FCF 73.5x vs. a median of 18.8x and EV/EBITDA 21.2x vs. a median of 15.0x.
Key Financial Data